摘要
Copanlisib是一种新型磷脂酰肌醇-3激酶抑制剂,由德国拜耳公司开发。基于Ⅱ期临床试验结果,美国FDA于2017年9月14日批准其上市,用于既往已接受至少2次治疗的复发性或难治性滤泡性淋巴瘤患者。本文对其作用机制、药效学和药动学、临床研究及安全性评价进行了归纳总结。
Copanlisib,developed by Bayer,is a new type of phosphatidyl inositol-3 kinase inhibitor.On September 14,2017,the US FDA granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies based on the results of a phase Ⅱ trial. In this paper,we summarized the mechanism of action,pharmacokinetic and pharmacodynamic characteristics,clinical trials and adverse effects of copanlisib.
作者
刘芳
杜小莉
LIU Fang;DU Xiao-li(Peiking Union Medical College Hospital,Peiking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2018年第24期2869-2872,共4页
Chinese Journal of New Drugs
